Walter S. Woltosz Sells 20,000 Shares of Simulations Plus, Inc. (NASDAQ:SLP) Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $33.51, for a total transaction of $670,200.00. Following the transaction, the director now owns 3,344,157 shares in the company, valued at approximately $112,062,701.07. The trade was a 0.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Simulations Plus Trading Down 0.7 %

Shares of Simulations Plus stock opened at $33.32 on Friday. Simulations Plus, Inc. has a twelve month low of $23.01 and a twelve month high of $51.22. The stock has a market cap of $670.10 million, a price-to-earnings ratio of 83.30 and a beta of 1.13. The company has a fifty day moving average price of $28.64 and a 200 day moving average price of $30.37.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. The company’s revenue was up 22.5% compared to the same quarter last year. Analysts forecast that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.

Institutional Trading of Simulations Plus

Several large investors have recently bought and sold shares of SLP. Fifth Third Bancorp lifted its position in shares of Simulations Plus by 33.8% during the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock worth $36,000 after purchasing an additional 375 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Simulations Plus by 4.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company’s stock worth $254,000 after buying an additional 380 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Simulations Plus by 53.6% in the 4th quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after buying an additional 427 shares during the last quarter. Pitcairn Co. grew its stake in shares of Simulations Plus by 10.8% during the fourth quarter. Pitcairn Co. now owns 7,310 shares of the technology company’s stock valued at $204,000 after acquiring an additional 711 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Simulations Plus by 14.3% during the fourth quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock worth $159,000 after acquiring an additional 713 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. StockNews.com raised shares of Simulations Plus from a “sell” rating to a “hold” rating in a research note on Monday, April 28th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. Finally, KeyCorp upped their price target on Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.00.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.